Literature DB >> 3936186

The demand for prescription drugs as a function of cost-sharing.

A Leibowitz, W G Manning, J P Newhouse.   

Abstract

This paper estimates how cost-sharing affects the use of prescription drugs. The data for this analysis are derived from the Rand Health Insurance Experiment (HIE), a randomized controlled trial that randomly assigned participants to insurance plans with varying coinsurance rates and deductibles. Therefore, the cost-sharing they faced was independent of their health and demographic characteristics. The paper used HIE data from four sites to estimate how drug expenditures vary by insurance plan, and to compare the plan response for drugs with that for all ambulatory expenses. The findings show that: (1) individuals with more generous insurance buy more prescription drugs; (2) the cost-sharing response for drugs is similar to the response for all ambulatory medical services; (3) the Dayton, Ohio site had significantly greater drug expenditures per capita than the other sites studied and a significantly higher proportion of drugs sold by physicians; and (4) the proportion of brand-name drugs among all drugs purchased in pharmacies was not a function of insurance plan. In the Dayton, Ohio site, a significantly higher proportion of the drugs purchased in pharmacies were brand-name rather than generic.

Entities:  

Mesh:

Year:  1985        PMID: 3936186     DOI: 10.1016/0277-9536(85)90161-3

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  40 in total

1.  Managing hypertension in patients with renal disease and diabetes.

Authors:  A Bell
Journal:  CMAJ       Date:  2000-05-30       Impact factor: 8.262

2.  Patient compliance with drug therapy for diabetic nephropathy.

Authors:  D Hughes; B Manns
Journal:  CMAJ       Date:  2000-05-30       Impact factor: 8.262

3.  Managing hypertension in patients with renal disease and diabetes.

Authors:  R Grad; S Hanley
Journal:  CMAJ       Date:  2000-05-30       Impact factor: 8.262

4.  Access to the morning-after pill in BC.

Authors:  B Osmond
Journal:  CMAJ       Date:  2000-05-30       Impact factor: 8.262

5.  Access to the morning-after pill in BC.

Authors:  W D Gutowski
Journal:  CMAJ       Date:  2000-05-30       Impact factor: 8.262

Review 6.  The effect of managed care on prescription drug costs and benefits.

Authors:  A Lyles; F B Palumbo
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

7.  Impact of consumer fees on drug utilisation.

Authors:  D G Smith; D M Kirking
Journal:  Pharmacoeconomics       Date:  1992-10       Impact factor: 4.981

8.  Economic impact of cost-containment strategies in third party programmes in the US (part I).

Authors:  C E Reeder; E W Lingle; R M Schulz; R P Mauch; B S Nightengale; C A Pedersen; M L Watrous; S E Zetzl
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

9.  Prescription cost sharing: economic and health impacts, and implications for health policy.

Authors:  R A Levy
Journal:  Pharmacoeconomics       Date:  1992-09       Impact factor: 4.981

Review 10.  Cost of pharmacological care of the elderly: implications for healthcare resources.

Authors:  Ciaran O'Neill; Carmel M Hughes; James Jamison; Anna Schweizer
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.